Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methicillin-resistant Staphylococcus aureus (MRSA) is a group of Gram-positive bacteria notable for its resistance to beta-lactam antibiotics. It is a human pathogen responsible for a range of infections, from mild skin conditions to severe diseases. Resistance arises through the mecA gene encoding an altered penicillin-binding protein (PBP2a) with low affinity for beta-lactams. MRSA is globally prevalent and associated with significant morbidity/mortality.
Resistance to beta-lactam antibiotics due to the presence of the mecA gene, which encodes an altered penicillin-binding protein (PBP2a) with low affinity for beta-lactams.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methicillin-resistant Staphylococcus aureus (MRSA).